World Leaders in Immune System Monitoring with Novel Molecular Biomarkers to Improve Sepsis Outcomes
Today, there is a high unmet need within the health care community worldwide for improved tools that will identify sepsis as early as possible and match the right treatment at the right time. Sepsis is a leading cause of death in both the developed and developing worlds.
Immunexpress is a molecular diagnostics company developing accurate clinical assays for the personalized management of immune disorders with a focus on:
- • Early detection and personalized management of sepsis patients
- • Early identification of sepsis in patients at risk
Immunexpress technology is based on proprietary immune system blood biomarkers for adaptation to new and existing clinical diagnostic platforms (multiplex qRT-PCR and proteomic).
Immunexpress’s vision is to deliver its multiplex molecular assays on point-of-care (POC) platforms for rapid turnaround, improved patient outcomes, reduced healthcare costs, and more effective targeted therapies.
